Literature DB >> 28210888

Double-carbapenem combination as salvage therapy for untreatable infections by KPC-2-producing Klebsiella pneumoniae.

M Souli1, I Karaiskos2, A Masgala3, L Galani2, E Barmpouti2, H Giamarellou4.   

Abstract

We report our experience using the double-carbapenem combination as salvage therapy for patients with untreatable infections caused by KPC-2- producing Klebsiella pneumoniae. A total of 27 patients in two institutions in Athens, Greece suffering from complicated urinary tract infections (16) with or without secondary bacteraemia (four and 12 respectively), primary (six) or catheter-related bloodstream infections (two), HAP or VAP (two) and external ventricular drainage infection (one) were treated exclusively with ertapenem and high-dose prolonged infusion meropenem because in-vitro active antimicrobials were unavailable (19) or failed (four) or were contraindicated (six). Most patients presented with severe infections with median APACHE II score of 17 and 11 of those patients (40.7%) had severe sepsis (five) or septic shock (six). The clinical and microbiological success was 77.8 and 74.1% respectively. Crude mortality was 29.6% with attributable mortality of 11.1%. Adverse events, none of them severe, were reported in four patients (14.8%). The double-carbapenem combination as an exclusive regimen represents a safe and valid salvage therapy for untreatable infections by extensively- or pandrug-resistant KPC-producing K.pneumoniae.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28210888     DOI: 10.1007/s10096-017-2936-5

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  30 in total

1.  Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case-control-control study.

Authors:  D R Giacobbe; V Del Bono; E M Trecarichi; F G De Rosa; M Giannella; M Bassetti; A Bartoloni; A R Losito; S Corcione; M Bartoletti; E Mantengoli; C Saffioti; N Pagani; S Tedeschi; T Spanu; G M Rossolini; A Marchese; S Ambretti; R Cauda; P Viale; C Viscoli; M Tumbarello
Journal:  Clin Microbiol Infect       Date:  2015-08-14       Impact factor: 8.067

2.  Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study.

Authors:  Mario Tumbarello; Enrico Maria Trecarichi; Francesco Giuseppe De Rosa; Maddalena Giannella; Daniele Roberto Giacobbe; Matteo Bassetti; Angela Raffaella Losito; Michele Bartoletti; Valerio Del Bono; Silvia Corcione; Giuseppe Maiuro; Sara Tedeschi; Luigi Celani; Chiara Simona Cardellino; Teresa Spanu; Anna Marchese; Simone Ambretti; Roberto Cauda; Claudio Viscoli; Pierluigi Viale
Journal:  J Antimicrob Chemother       Date:  2015-04-21       Impact factor: 5.790

3.  Effectiveness of a double-carbapenem regimen for infections in humans due to carbapenemase-producing pandrug-resistant Klebsiella pneumoniae.

Authors:  Helen Giamarellou; Lambrini Galani; Fotini Baziaka; Ilias Karaiskos
Journal:  Antimicrob Agents Chemother       Date:  2013-02-25       Impact factor: 5.191

4.  Successful Treatment of Carbapenemase-Producing Pandrug-Resistant Klebsiella pneumoniae Bacteremia.

Authors:  Jose F Camargo; Jacques Simkins; Thiago Beduschi; Akin Tekin; Laura Aragon; Armando Pérez-Cardona; Clara E Prado; Michele I Morris; Lilian M Abbo; Rafael Cantón
Journal:  Antimicrob Agents Chemother       Date:  2015-10       Impact factor: 5.191

5.  Validation of a combined comorbidity index.

Authors:  M Charlson; T P Szatrowski; J Peterson; J Gold
Journal:  J Clin Epidemiol       Date:  1994-11       Impact factor: 6.437

6.  In vitro evaluation of dual carbapenem combinations against carbapenemase-producing Enterobacteriaceae.

Authors:  Laurent Poirel; Nicolas Kieffer; Patrice Nordmann
Journal:  J Antimicrob Chemother       Date:  2015-09-27       Impact factor: 5.790

Review 7.  Treating infections caused by carbapenemase-producing Enterobacteriaceae.

Authors:  L S Tzouvelekis; A Markogiannakis; E Piperaki; M Souli; G L Daikos
Journal:  Clin Microbiol Infect       Date:  2014-07-12       Impact factor: 8.067

8.  Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012.

Authors:  R P Dellinger; Mitchell M Levy; Andrew Rhodes; Djillali Annane; Herwig Gerlach; Steven M Opal; Jonathan E Sevransky; Charles L Sprung; Ivor S Douglas; Roman Jaeschke; Tiffany M Osborn; Mark E Nunnally; Sean R Townsend; Konrad Reinhart; Ruth M Kleinpell; Derek C Angus; Clifford S Deutschman; Flavia R Machado; Gordon D Rubenfeld; Steven Webb; Richard J Beale; Jean-Louis Vincent; Rui Moreno
Journal:  Intensive Care Med       Date:  2013-01-30       Impact factor: 17.440

9.  The utility of acute physiology and chronic health evaluation II scores for prediction of mortality among intensive care unit (ICU) and non-ICU patients with methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Vanessa Stevens; Thomas P Lodise; Brian Tsuji; Meagan Stringham; Jill Butterfield; Elizabeth Dodds Ashley; Kristen Brown; Alan Forrest; Jack Brown
Journal:  Infect Control Hosp Epidemiol       Date:  2012-04-13       Impact factor: 3.254

10.  Use of boronic acid disk tests to detect extended- spectrum beta-lactamases in clinical isolates of KPC carbapenemase-possessing enterobacteriaceae.

Authors:  Athanassios Tsakris; Aggeliki Poulou; Katerina Themeli-Digalaki; Evangelia Voulgari; Theodore Pittaras; Danai Sofianou; Spyros Pournaras; Dimitra Petropoulou
Journal:  J Clin Microbiol       Date:  2009-09-02       Impact factor: 5.948

View more
  13 in total

1.  Pitfalls of defining combination therapy for carbapenem-resistant Enterobacteriaceae in observational studies.

Authors:  D R Giacobbe; A E Maraolo; C Viscoli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-05-21       Impact factor: 3.267

Review 2.  Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.

Authors:  Jesús Rodríguez-Baño; Belén Gutiérrez-Gutiérrez; Isabel Machuca; Alvaro Pascual
Journal:  Clin Microbiol Rev       Date:  2018-02-14       Impact factor: 26.132

Review 3.  Treatment Options for Carbapenem- Resistant Gram-Negative Infections.

Authors:  Moritz Fritzenwanker; Can Imirzalioglu; Susanne Herold; Florian M Wagenlehner; Klaus-Peter Zimmer; Trinad Chakraborty
Journal:  Dtsch Arztebl Int       Date:  2018-05-21       Impact factor: 5.594

4.  Effectiveness of a double-carbapenem combinations against carbapenem-resistant Gram-negative bacteria.

Authors:  Jiayue Lu; Yan Qing; Ning Dong; Congcong Liu; Yu Zeng; Qiaoling Sun; Qiao Shentu; Lixing Huang; Yingqian Wu; Hongwei Zhou; Zhangqi Shen; Rong Zhang
Journal:  Saudi Pharm J       Date:  2022-03-14       Impact factor: 4.562

5.  Modelling of the transmission dynamics of carbapenem-resistant Klebsiella pneumoniae in hospitals and design of control strategies.

Authors:  Suttikiat Changruenngam; Charin Modchang; Dominique J Bicout
Journal:  Sci Rep       Date:  2022-03-09       Impact factor: 4.996

Review 6.  Carbapenem-Resistant Enterobacterales: Considerations for Treatment in the Era of New Antimicrobials and Evolving Enzymology.

Authors:  Maxwell J Lasko; David P Nicolau
Journal:  Curr Infect Dis Rep       Date:  2020-02-07       Impact factor: 3.725

7.  Role of Double-Carbapenem Regimen in the Treatment of Infections due to Carbapenemase Producing Carbapenem-Resistant Enterobacteriaceae: A Single-Center, Observational Study.

Authors:  F Cancelli; A Oliva; M De Angelis; M T Mascellino; C M Mastroianni; V Vullo
Journal:  Biomed Res Int       Date:  2018-11-18       Impact factor: 3.411

8.  Double carbapenem as a rescue strategy for the treatment of severe carbapenemase-producing Klebsiella pneumoniae infections: a two-center, matched case-control study.

Authors:  Gennaro De Pascale; Gennaro Martucci; Luca Montini; Giovanna Panarello; Salvatore Lucio Cutuli; Daniele Di Carlo; Valentina Di Gravio; Roberta Di Stefano; Guido Capitanio; Maria Sole Vallecoccia; Piera Polidori; Teresa Spanu; Antonio Arcadipane; Massimo Antonelli
Journal:  Crit Care       Date:  2017-07-05       Impact factor: 9.097

9.  Mortality, clinical and microbiological response following antibiotic therapy among patients with carbapenem-resistant Klebsiella pneumoniae infections (a meta-analysis dataset).

Authors:  Akosua A Agyeman; Phillip J Bergen; Gauri G Rao; Roger L Nation; Cornelia B Landersdorfer
Journal:  Data Brief       Date:  2019-11-30

Review 10.  Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems.

Authors:  Stamatis Karakonstantis; Evangelos I Kritsotakis; Achilleas Gikas
Journal:  Infection       Date:  2020-09-01       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.